Member Content

Antibody Drug Conjugates (ADCs) Platforms Could See Resurgence of Interest with Potential M&A Deal

by Alex Wolsky | Jun 30, 2022

Thematic Snapshot – Antibody Drug Conjugates (ADCs)
Biotech M&A has been an intriguing area recently, as outlined in the Quarterly Brief, and one potential deal – Merck’s $20B+ buy of SeaGen – could spark a rally or resurgence of interest in a gr...

Please login to continue reading this article.

Options Hawk Max

$399 | 30 days

Options Hawk Trading Hub Live Chat
Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
Live Mock Portfolio
1 on 1 Access
Hawk’s Trader Toolbox
Street Research
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
Weekly and Monthly OpEx Sheets
Notable Options Database
OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$199 | 30 days

Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
OptionsHawk Quarterly Market Brief

More About this Plan